A multidisciplinary team at Harvard's Wyss Institute leveraged AI-enabled molecular modeling and physics-based simulations to identify and optimize bemcentinib derivatives with antiviral activity across multiple respiratory coronaviruses. This approach aimed to overcome vaccine access inequities and viral variants with increased infectivity and immune evasion. The work lays the foundation for orally available drugs capable of rapid deployment during coronavirus outbreaks and pandemics.